EXECUTIVE TEAM
Oceana Therapeutics, Inc. is dedicated to providing health professionals with life-changing specialty therapies through the innovation, excellence and commitment of our management team. The primary responsibilities of our management committee are to provide oversight, strategic guidance, counseling and product direction.
We are organized under the direction of a management committee, which currently consists of the following members:
John T. Spitznagel
Chief Executive Officer & Chairman
Mr. Spitznagel most recently served as Chairman and Chief Executive officer for Esprit Pharma, Inc. a specialty pharmaceutical company focusing on the sale and marketing of pharmaceutical therapies to the genito-urinary market. After co-founding the Company in mid-2005, John was able to oversee the Esprit's acquisition, marketing and growth strategies, which led to the sale of Esprit to Allergan, Inc. for $370 million in October 2007. Previously, Mr. Spitznagel was Chairman and Chief Executive Officer of ESP Pharma, a specialty pharmaceutical company focused on acquiring in-market and late stage drugs for the acute care market. Within three years of initiating operations, ESP was acquired by Protein Design Labs for approximately $514 million in March 2005. Prior to ESP, John was President and Chief Executive Officer of Roberts Pharmaceuticals which was engaged in the acquisition, development and marketing of specialty pharmaceuticals. He joined Roberts in 1996 and is credited with leading that company through a dramatic turnaround in profitability. John ultimately engineered the successful merger of Roberts with Shire Pharmaceuticals in 1999 for approximately $1.2 billion ( a nearly four-fold expansion of market value during his tenure). Prior to his work at Roberts, John served as President of the Reed and Carnrick division of Block Drug from 1990 - 1995, where he also was responsible for a successful turnaround and sale of the division. John began his career in 1964 at Warner-Lambert in sales and marketing and spent nearly ten years at Hoffmann-La Roche and ten years at American Home Products where he was Senior Vice President of Marketing and Sales for Wyeth.
Mr. Spitznagel is a director at Wynden Pharmaceuticals, IRX Therapeutics and Chairman at Barbeau Pharmaceuticals. He is a trustee for Rider University where he earned a Bachelor's degree in Liberal Arts. John also holds an M.B.A. from Fairleigh Dickinson University.
top
David S. Tierney, M.D.
President & Chief Operating Officer
David S. Tierney, MD, was the President, Chief Executive Officer and a Director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. During his time at Élan Dr Tierney was involved in the development of numerous successful NDAs. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine.
Dr Tierney serves as non-executive Chairman of Bioject Inc (BJCT: NASDAQ) and is a member of the board of directors of Catalyst Pharmaceutical Partners (CPRX: NASDAQ) and Nexmed, Inc (NEXM: NASDAQ).
top
Andrew J. Einhorn
Chief Financial Officer
Mr. Einhorn is a corporate finance professional with an extensive background in investment and commercial banking and public accounting. He possesses broad experience in finance, domestic capital markets and financial analysis. From mid-2005 to October 2007, Mr. Einhorn served as Executive Vice President and Chief Financial Officer for Esprit Pharma, Inc., a genito-urinary focused specialty pharmaceutical company. While at Esprit, Mr. Einhorn played a key role in setting the strategic direction of the Company and in the negotiation and execution of the Company's acquisitions and related financing. He played a major role in the Company's sale to Allergan, Inc. while simultaneously preparing the Company for an initial public offering. Mr. Einhorn previously held the position of Executive Vice President and Chief Financial Officer of ESP Pharma, Inc. where he oversaw the finance and accounting functions, and played a key role in the Company's successful financing and acquisition activities, including the sale of ESP to Protein Design Labs in 2005. Andy was awarded the coveted 2005 CFO Award for "Deal of the Year" by the New Jersey Technology Council for the ESP sale transaction.
Earlier, Mr. Einhorn served as Managing Director for Credit Lyonnais Securities where his responsibilities included originating and structuring fixed income public transactions, private placements, and euro-denominated debt for US issuers. Previously, he held the positions of Managing Director with PNC Capital Markets and Vice President with Chase Securities and Chase Manhattan Bank. In these positions, Mr. Einhorn actively engaged in several financial and corporate banking activities, including debt capital market transactions, high yield bond financings, private equity transactions and international tax-effective financing. He also served as Vice President with Bankers Trust Company and as a Senior Accountant with Touche Ross & Company where he was responsible for managing audits for healthcare and other industry clients.
Mr. Einhorn is a Certified Public Accountant and a graduate of The American University where he completed a double major in Finance and Accounting.
top
Gregory J. Stokes
Executive Vice President, Business Development
From June 2005 to October 2007, Mr. Stokes served as President and Chief Operating Officer of Esprit Pharma, Inc., a specialty pharmaceutical company focusing in the genito-urinary therapeutic area. Under Mr. Stokes' leadership, Esprit grew to over $50 million in revenues and fielded a sales force of over 200 professionals. In October 2007 Esprit was sold to Allergan, Inc. for $370 million. Previously, Mr. Stokes served as Vice President of Corporate Development for ESP Pharma, a specialty pharmaceutical company focused in the acute care market, where was in the forefront of identifying and completing acquisition transactions contributing to the successful growth of the Company's portfolio of products and development drugs. Additionally, Greg played a key role in the sale of ESP to Protein Design Labs in March 2005. Prior to joining ESP in 2002, Mr. Stokes served as Director of Business Development with Shire Pharmaceuticals Group, Plc where he executed business development strategies for commercial opportunities with regard to both in-and out-licensing prospects, joint ventures, acquisitions, co-promotion and co-marketing arrangements and investments in late-stage pipeline compounds. Previously, he was employed by Roberts Pharmaceutical Corporation, which merged into Shire at year-end 1999. While at Roberts, Greg advanced in position from a Specialty Hospital Sales Representative to Product Manager, Group Product Manager, and to Senior Manager, Business Development and Strategic Planning. During his tenure with Roberts, he participated in the successful assessment of opportunities to acquire in-market and development stage specialty therapeutics, thus facilitating a significant expansion of Roberts' portfolio of marketed and pipeline products, plus the Company's emergence as a partner-of-choice for product acquisition and marketing alliances, and Roberts' dramatic turnaround and growth in profitability. Prior to Roberts, Mr. Stokes served as a Sales Representative for Reed & Carnrick Pharmaceuticals, which was acquired by German based Schwarz Pharma AG.
Mr. Stokes holds a B.A. degree from the University of Pennsylvania and received his MBA and J.D. degrees from Rutgers University. He has extensive international pharmaceutical experience and was admitted to the New Jersey State Bar in 1999.
top
Mark H. Janofsky
Vice President Finance & Controller
Mr. Janofsky has over 30 years experience as a financial executive and corporate controller, primarily in the pharmaceutical, electronics and merger and acquisition sectors. Mr. Janofsky comes to Oceana with a proven track record in managing multi-million dollar financial functions with strong team leadership, analytical, strategic and change management skills. Mr. Janofsky's most recent position was Controller for Esprit Pharma where he assisted the CFO in providing financial leadership to corporate development and reporting to a VC-backed investor syndicate. He was also responsible for analysis, banking relations, audits, supply chain accounting, CMS compliance and managed care strategizing and reporting. He served as point person in IPO readiness and divestiture activity with the investment community. Before that, Mr. Janofsky joined ESP Pharma, where he served in a similar capacity before it was acquired by PDL BioPharma. Prior to his position at ESP, Mr. Janofsky was engaged as a controller/forensic accountant for Galderma US, a subsidiary of Nestle, SA. In this role he installed necessary controls and the reporting protocols to monitor CRO and internal product development. Mr. Janofsky's first foray into pharmaceuticals began when he joined Roberts Pharmaceuticals as Corporate Controller, tasked with public reporting and implementing operational controls. Mr. Janofsky was a key member of the Roberts' financial turnaround from 1996 through 1999, and the merger team with Shire US in 2000. After the merger, he continued in a similar role with Shire, rebuilding their US financial function. Earlier in his career, he joined defense contractor Nytronics/Struthers-Dunn and rose through the ranks, serving a dual role as Controller for two $70 million electronics divisions as well as managing the CFO functions for the parent entity, a conglomerate which had $400 million in sales and controlled 23 manufacturing operations. Nytronics was sold to a competitor in 1996. He began his career in public accounting, then later joined Children's Television Workshop. Mr. Janofsky is a graduate of Rutgers University with a BA degree, with honors, and the Columbia University Graduate School of Business with a Masters in Business Administration. He is a Certified Public Accountant in New York State.
top
Matthew L. Rue
Senior Vice President Marketing
Mr. Rue has served in a marketing capacity for several specialty pharmaceutical firms, gaining extensive experience in product development, building and aligning sales forces, creating effective marketing materials, product launches and market research. Most recently, he joined David Tierney at Valera Pharmaceuticals as Vice President, Marketing in 2000. He was a key player in preparing the marketing and sales forecasts which was pivotal in securing the venture capital necessary to finish out the clinical trials and prepare for the launch of Valera's lead product, Vantas, a one year implant to treat prostate cancer. While at Valera, Mr. Rue was an active contributor to business development, clinical trial design, creating advocacy panels and developing sales territories. He had two product managers as direct reports. Valera was acquired by Indevus Pharmaceuticals in April 2007. Before that, Mr. Rue was director of Marketing at Roberts Pharmaceutical, a specialty pharma firm with drugs in hematology, neurology and gastroenterology. He had three product managers as reports and was actively involved in developing positionings and sales force re-alignments for all the promoted drugs. Revenues for these products increased significantly under his tenure. Roberts was acquired by Shire Pharmaceuticals in March 2000. Prior to his Roberts position, Mr. Rue served as senior Product Manager for Reed & Carnrick, a specialty pharma firm with promoted compounds in cardiology, gastroenterology and dermatology. Mr. Rue managed and launched several line extensions of Reed & Carnrick's OTC brands before switching over to prescription drugs. He was chosen to launch a newly approved treatment for actinic keratoses, which are pre-cancerous skin lesions. Reed & Carnrick was acquired by Schwarz Pharma in 1999. Mr. Rue began his pharmaceutical career at Schering-Plough, first as a market researcher, then as a product manager for several of their ethically promoted Rx-to-OTC products. He acquired a BFA degree in English from Emerson College.
top
Steven M. Bosacki
Senior Vice President, General Counsel
Mr. Bosacki was most recently Vice President and General Counsel for Esprit Pharma, Inc., a specialty pharmaceuticals company focusing on the sale and marketing of therapies for the genito-urinary market, including its flagship product Sanctura. Mr. Bosacki was actively involved in the acquisition and divestiture of several products for Esprit, and in connection with the ultimate sale of the company to Allergan, Inc. Prior to joining Esprit, Mr. Bosacki was Senior Vice President of Commercial Operations for Saturn Pharmaceuticals, the company which had originally acquired the rights to Sanctura from Indevus Pharmaceuticals. Previously, Mr. Bosacki was Vice President of Client and Support Services for Cardinal Health. Cardinal Health acquired Boron Lepore in 2004. At the time of the acquisition, Mr. Bosacki was Vice President and General Manager of the Field Force Logistics division of Boron Lepore which had planned and executed over 140,000 meetings and had annual revenues of over $80 million. During his tenure there, from 1998 to 2004, Mr. Bosacki worked with numerous pharmaceutical clients such as Bristol Myers-Squibb, Pfizer, Roche, Sanofi and Shire. He was also a member of the Operating Board, responsible for the integration of various business units in the Boron Lepore portfolio. Prior to joining Boron Lepore, Mr. Bosacki was an attorney in private practice in transactional, banking and general corporate law. Mr. Bosacki is a member of the State Bar of New Jersey and was admitted to the Law Society of Upper Canada (Ontario). He received a Bachelor of Commerce and an MBA from the University of Windsor and also has a J.D. and an LL.B having completed joint laws degrees from the University of Detroit and University of Windsor.
top
|
